Substack · John Hempton's Newsletter · John Hempton
A non-consensus thesis: the forthcoming demise of Bristol Myers Squibb.
A first proof point.
Since publication +6.2% α +4.1 pp vs S&P 500 · USD
US · 1 entry · 1 publication
Bristol Myers Squibb CO
No entry states a stance.
Free during launch: log in or sign up with your email to see it.
Sign up freeSubstack · John Hempton's Newsletter · John Hempton
A first proof point.
Since publication +6.2% α +4.1 pp vs S&P 500 · USD
Prices as of the Oct 27, 2026 close. Past performance does not guarantee future results. Price-only, excluding dividends, in local currency. Data may be delayed or inaccurate. Not investment advice. How it is calculated.